#None #Telix Pharmaceuticals #Hagens Berman #TLX Lawsuit

Hagens Berman Urges Telix Investors to Act Promptly Amid Legal Setbacks

Investors in Telix Pharmaceuticals Ltd., trading under the symbol TLX, are being urged to act swiftly as the deadline for moving to court as lead plaintiff in a securities class action lawsuit approaches. National shareholder rights law firm Hagens Berman is reminding impacted investors that the deadline is set for January 9, 2026. This comes on the heels of significant regulatory challenges that have resulted in a sharp stock decline for the company.

The lawsuit stems from allegations that Telix and its executives misrepresented the progress of their prostate cancer drug candidates, TLX591 and TLX592. Following a series of unfortunate regulatory events, including an SEC subpoena and an FDA Complete Response Letter (CRL), Telix's stock suffered a staggering 21% drop. Now, the firm is calling upon investors who have faced financial losses to step forward and assert their rights.

Understanding the Complaints Against Telix

Reed Kathrein, a partner at Hagens Berman and the lead attorney in this case, emphasized the seriousness of the allegations. The complaint reveals two primary areas of concern:

1. Regulatory Compliance Issues: Telix's management purportedly overstated the advancements in their drug development, creating a disconnect between their public statements and the actual progress. Claims of significant achievements were reportedly contradicted by regulatory challenges faced by their third-party manufacturing partners, as indicated by formally documented deficiencies (Form 483).

2. Supply Chain Transparency: Investors allege that Telix concealed crucial weaknesses in their supply chain and manufacturing processes. Specifically, the CRL issued by the FDA highlighted deficiencies related to Chemistry, Manufacturing, and Controls (CMC) which, if properly disclosed, could have significantly impacted investor decisions during the critical Class Period.

The Impact of Regulatory News

The timeline of problematic events is an important aspect of this case. On July 22, 2025, Telix disclosed an SEC subpoena concerning its disclosures around the development of TLX591 and TLX592. This event marked the onset of scrutiny regarding their drug development claims and was followed by the FDA's CRL on August 28, 2025, rejecting the application due to identified deficiencies. These events notably shook investor confidence, leading to a sharp decline in stock value.

Next Steps for Investors

Hagens Berman is actively advising investors who purchased Telix’s American Depositary Shares (ADS) during the Class Period—from February 21, 2025, to August 28, 2025—pertaining to their rights in the face of these misrepresentations. Interested parties are encouraged to contact the firm to discuss potential actions and recoveries.

The law firm has a strong reputation for securing substantial recoveries for investors, asserting that the consequences of the undisclosed flaws in Telix’s supply chain and therapeutic progress warrant serious attention. Investors are advised to reach out to Reed Kathrein directly at 844-916-0895 or via email to ensure their voices are heard before the looming deadline.

In conclusion, the legal actions against Telix Pharmaceuticals highlight the critical need for transparency in the pharmaceutical industry, particularly for companies involved in high-stakes therapeutic developments. As the January 9 deadline approaches, affected investors must act quickly to engage with Hagens Berman and seek justice for the challenges they have faced.

For more information about this case, regularly updated insights, and resources, investors can visit the Hagens Berman website or follow them on social media at @ClassActionLaw.